Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary results of a phase I/II study.

被引：0
|
作者：
Vey, N
Dreyfus, F
Guerci, A
Fenaux, P
Dombret, H
Burnett, AK
Bosly, A
Feremans, W
Bowen, DT
Heiskala, M
机构：
[1] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales
[2] Clin Univ Mt Godinne, Yvoir, Belgium
[3] Erasme Univ Hosp, Brussels, Belgium
[4] Ninewells Hosp, Dundee DD1 9SY, Scotland
[5] Celll Therapeut Inc, Clin, Seattle, WA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1433
引用
收藏
页码：401A / 402A
页数：2
相关论文
共 50 条
  • [1] Trisenox® (Arsenic trioxide) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary results of a phase II study.
    Vey, N
    Blaise, D
    Damaj, G
    Gastaut, JA
    Garzon, F
    Paradise, C
    Panning, L
    BLOOD, 2002, 100 (11) : 342B - 342B
  • [2] Trisenox® (arsenic trioxide) in patients with Myelodysplastic syndromes (MDS):: Preliminary results of a phase 1/2 study.
    Vey, N
    Dreyfus, F
    Guerci, A
    Fenaux, P
    Dombret, H
    Burnett, A
    Bosly, A
    Feremans, W
    Bowen, D
    Garzon, F
    BLOOD, 2003, 102 (11) : 422A - 423A
  • [3] Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary findings in a phase 2 clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Ellison, R
    BLOOD, 2003, 102 (11) : 423A - 423A
  • [4] Trisenox® (arsenic trioxide, ATO) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary findings in a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Paradise, C
    BLOOD, 2002, 100 (11) : 790A - 790A
  • [5] Arsenic trioxide in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Ellison, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 561S - 561S
  • [6] The impact of GM-CSF on arsenic trioxide (As2O3, trisenox) therapy in patients with myelodysplastic syndrome (MDS): Preliminary results of a phase II study.
    Mavromatis, Blanche H.
    Kessler, Craig M.
    Cheson, Bruce D.
    Sein, Aung
    Sharp, Stewart A.
    BLOOD, 2006, 108 (11) : 299B - 299B
  • [7] Prolonged administration of arsenic trioxide (Trisenox®) for or patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) at MD Anderson cancer center:: A phase II study.
    Beran, M
    Verstovsek, S
    Kornblau, M
    Estey, EH
    Giles, F
    Garcia-Manero, G
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 266B - 266B
  • [8] Arsenic trioxide (Trisenox®) with/without thalidomide in patients with myelodysplastic syndromes (MDS) produces hematologic improvement (HI).
    Raza, A
    Lisak, L
    Billmeier, J
    Akbar, S
    Washeed, K
    Mumtaz, M
    Reddy, P
    Galili, N
    BLOOD, 2004, 104 (11) : 261B - 262B
  • [9] Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes
    A List
    M Beran
    J DiPersio
    J Slack
    N Vey
    C S Rosenfeld
    P Greenberg
    Leukemia, 2003, 17 : 1499 - 1507
  • [10] Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromes
    List, A
    Beran, M
    DiPersio, J
    Slack, J
    Vey, N
    Rosenfeld, CS
    Greenberg, P
    LEUKEMIA, 2003, 17 (08) : 1499 - 1507
12345